BioWorld

Sep. 15, 2003

Neurocrine Biosciences Brings In $200M In Oversold Public Offering

Marching ahead with its non-benzodiazepine insomnia drug indiplon, Neurocrine Biosciences Inc. said it priced an offering of 3.75 million shares at $53 per share, for net proceeds of about $200 million. (BioWorld Today) Read More

Tercica, Armed With Genentech Technology, Seeks $86.25M IPO

Ligand Gains $47M In Private Sale To Expand Commercial Activities

Alexion Raises $44 Million For Development Of Pipeline Drugs

Axonyx Placement Garners $25M For Second Phase III

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...